Effects of progestins on cardiovascular diseases: the haemostatic system.
The effect of progestin-only therapy on the haemostatic system has mainly been studied in premenopausal women. Although these studies are difficult to compare, most authors agree that there is no consistent pattern of effects on haemostasis. Oestrogen-progestin combinations have been extensively studied in pre- (combined oral contraceptives) and postmenopausal women (sequential and continuous combined hormone replacement therapy), but mostly with emphasis on the effects of oestrogens. Comparative studies into the differential effects of progestins in combined preparations are scarce. Based on these studies, there is evidence for modifying effects of progestins on oestrogen-induced changes, particularly on fibrinogen, factor VII and the fibrinolytic system. The modifying effects appear to vary among certain progestins, the variation being most likely due to differential effects on lipid metabolism. The clinical interpretation of steroid-induced effects on the haemostatic system is difficult. Retrospective analyses linking certain patterns of haemostatic regulation to the risk of venous or arterial vascular diseases are subject to bias, and no interventional studies are yet available. In the absence of such prospective studies and well-designed comparative studies, the available data do not support the notion of a superiority of certain progestins with regard to cardiovascular risks of combined preparations.
Winkler
U H
UH
Department of Obstetrics and Gynaecology, Friedrich-Ebert Hospital, Neumünster, Germany.
D002318:Cardiovascular Diseases / Q000209:etiology* / Q000517:prevention & control; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004967:Estrogens / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006487:Hemostasis / Q000187:drug effects* / Q000502:physiology; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D011372:Progestins / Q000494:pharmacology* / Q000627:therapeutic use
D003277:Contraceptives, Oral, Combined; D004967:Estrogens; D011372:Progestins